-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 PpXGAgLnl7eDoEoYQMTpRdHjRXbZtbxZbYZzKwy3FSJU+eMyoZH2xUJB2D+7GiXI
 AsrLJFbFgTI+WZsTCmeFvQ==

<SEC-DOCUMENT>0000200406-08-000132.txt : 20080912
<SEC-HEADER>0000200406-08-000132.hdr.sgml : 20080912
<ACCEPTANCE-DATETIME>20080912144006
ACCESSION NUMBER:		0000200406-08-000132
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20080908
ITEM INFORMATION:		Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
FILED AS OF DATE:		20080912
DATE AS OF CHANGE:		20080912

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			JOHNSON & JOHNSON
		CENTRAL INDEX KEY:			0000200406
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				221024240
		STATE OF INCORPORATION:			NJ
		FISCAL YEAR END:			0114

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-03215
		FILM NUMBER:		081069059

	BUSINESS ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
		BUSINESS PHONE:		732-524-2455

	MAIL ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>poonannouncement.htm
<TEXT>
<html>
  <head>
    <title>poonannouncement.htm</title>
<!-- Licensed to: Johnson & Johnson-->
<!-- Document Created using EDGARizer 4.0.6.1 -->
<!-- Copyright 1995 - 2008 EDGARfilings, Ltd., an IEC company. All rights reserved -->
</head>
    <body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">UNITED
STATES</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SECURITIES
AND EXCHANGE COMMISSION</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">WASHINGTON,
DC 20549</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman">FORM
8-K</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CURRENT
REPORT</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
to Section 13 or 15(d) of the</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Securities
Exchange Act of 1934</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date of
report (Date of earliest event reported):&#160;&#160;September 8,
2008</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><img src="poonannouncement0.jpg" alt=""></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Exact
name of registrant as specified in its charter)</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">
          <tr>
            <td valign="top" width="27%" style="BORDER-TOP: #000000 0.5pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">New
      Jersey</font></div>
            </td>
            <td valign="top" width="33%" style="BORDER-TOP: #000000 0.5pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">I-3215</font></div>
            </td>
            <td valign="top" width="27%" style="BORDER-TOP: #000000 0.5pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">22-1024240</font></div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="27%" style="BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(State
      or Other Jurisdiction of Incorporation)</font></div>
            </td>
            <td valign="top" width="33%" style="BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Commission
      File Number)</font></div>
            </td>
            <td valign="top" width="27%" style="BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(IRS
      Employer Identification No.)</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">One
Johnson &amp; Johnson Plaza, New Brunswick, New
Jersey&#160;&#160;08933</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
of Principal Executive Offices) (Zip Code)</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Registrant&#8217;s
telephone number, including area code:&#160;&#160;732-524-0400</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Wingdings">o</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Wingdings">o</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Wingdings">o</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Wingdings">o</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))</font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div><br><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Item
5.02.&#160;&#160;Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
September 12, 2008, the Company announced that Christine A. Poon, 56, Vice
Chairman of the Board of Directors and Worldwide Chairman, Pharmaceuticals
Group, has announced plans to retire on March 1, 2009 from the Company and the
Board.&#160;&#160;Ms. Poon began her career with the Company in&#160;2000 and
was elected to the Company&#8217;s Board of Directors and named a Vice Chairman of the
Board in 2005.&#160;&#160;The related press release dated September 12, 2008 is
attached as Exhibit 99.1 to this Report.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SIGNATURES</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this Report to be signed on its behalf by the undersigned hereunto
duly authorized.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">
          <tr>
            <td align="left" valign="top" width="44%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" colspan="2" valign="top" width="32%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Johnson
      &amp; Johnson</font></div>
            </td>
            <td align="left" valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
          <tr>
            <td align="left" valign="top" width="44%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="top" width="29%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;(Registrant)</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
            </td>
            <td align="left" valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
          <tr>
            <td align="left" valign="top" width="44%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date:&#160;&#160;September
      12, 2008</font></div>
            </td>
            <td align="left" valign="top" width="3%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:</font></div>
            </td>
            <td align="left" valign="top" width="29%" style="BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/&#160;STEVEN
      M. ROSENBERG</font></div>
            </td>
            <td align="left" valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
          <tr>
            <td align="left" valign="top" width="44%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="bottom" width="29%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Steven
      M. Rosenberg</font></div>
            </td>
            <td align="left" valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
          <tr>
            <td align="left" valign="top" width="44%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="top" width="29%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Secretary</font></div>
            </td>
            <td align="left" valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
          <tr>
            <td align="left" valign="top" width="44%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="top" width="29%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">EXHIBIT
INDEX</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Exhibit
No.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<font style="DISPLAY: inline; TEXT-DECORATION: underline">Description</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">99.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Press release dated September 12, 2008</font></div>
  </body>
</html>


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1 CHARTER
<SEQUENCE>2
<FILENAME>announcement.htm
<TEXT>
<html>
  <head>
    <title>announcement.htm</title>
<!-- Licensed to: Johnson & Johnson-->
<!-- Document Created using EDGARizer 4.0.6.1 -->
<!-- Copyright 1995 - 2008 EDGARfilings, Ltd., an IEC company. All rights reserved -->
</head>
    <body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><br><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit
99.1</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Press
Contact:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Jeffrey
J. Leebaw</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 108pt"></font>732-524-3350</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Investor
Contacts:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Louise
Mehrotra&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Stan
Panasewicz</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 108pt"></font>732-524-6491&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;732-524-2524</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">FOR IMMEDIATE
RELEASE</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Christine
A. Poon Plans Retirement from Johnson &amp; Johnson in Early 2009</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>New Brunswick, NJ (September 12, 2008)
- -- Johnson &amp; Johnson said today that Christine A. Poon, 56, Vice Chairman of
the Board of Directors and Worldwide Chairman, Pharmaceuticals Group, has
announced plans to retire on March 1, 2009, from the Company and the Board,
after more than 23 years in the health care industry and eight years with the
Company.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>William C. Weldon, Chairman and CEO,
said, "Chris has been instrumental in helping to build Johnson &amp; Johnson's
pipeline of medicines to its place today as one of the world&#8217;s most
highly-regarded.&#160;&#160;We will certainly miss Chris' counsel, her
leadership focus in building our pharmaceuticals business and her constant quest
to bring better health and well-being to people around the world.&#160;&#160;She
has exhibited strong leadership and personal involvement in building a skilled
and diverse workforce.&#160;&#160;As a member of our Executive Committee and
Vice Chairman, Chris has helped to shape Johnson &amp; Johnson&#8217;s strategy and
vision for the future."</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>Ms. Poon began her career with Johnson
&amp; Johnson in November, 2000, as Company Group Chairman,
Pharmaceuticals.&#160;&#160;In August, 2001, she was promoted to the Executive
Committee and named Worldwide Chairman, Pharmaceuticals.&#160;&#160;Ms. Poon was
appointed Worldwide Chairman, Medicines &amp; Nutritionals, in October
2003.&#160;&#160;She was elected to the Johnson &amp; Johnson Board of Directors
and named a Vice Chairman of the Board in 2005.&#160;&#160;Prior to joining
Johnson &amp; Johnson, Ms. Poon spent 15 years at Bristol-Myers Squibb, where
her most recent position was President of International
Medicines.&#160;&#160;Ms. Poon is on the Board of Directors of Prudential
Financial, Inc., in Newark, NJ, and the Fox Chase Cancer Center in Philadelphia,
PA.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Mr.
Weldon said a timely announcement of pharmaceutical succession plans will be
made to ensure a smooth transition of Ms. Poon&#8217;s Pharmaceuticals Group
responsibilities.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">About Johnson &amp;
Johnson</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Caring
for the world, one person at a time&#8230;inspires and unites the people of Johnson
&amp; Johnson. We embrace research and science - bringing innovative ideas,
products and services to advance the health and well-being of people. Our
120,200 employees at more than 250 Johnson &amp; Johnson companies work with
partners in health care to touch the lives of over a billion people every day,
throughout the world.</font></div><br><br></body>
</html>


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>poonannouncement0.jpg
<TEXT>
begin 644 poonannouncement0.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"``^`.\#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#WE$3RT.Q>
M@_A%.,:#^!?RI4XB3_=%)(XC1G8A549))P!0+K8/+C_N+^5+Y<?]Q?RK#M/%
M5C>ZHEC;I*_F`E9@/D;'7%;N:$[ERIR@[25A/+3^XOY4GEI_<7\J?FL+5/%6
MF:3?I9W,A\TX+;1G8"<`MZ<TFTMPA"4W:*N;7EIW1?RI?+C_`+B_E0KAE!!R
M#T-/IDV&^6G]Q?RH\M/[B_E3J*`&^6G]Q?RH\M/[B_E3J*`&^6G]Q?RH\M/[
MB_E3J*`&^6G]Q?RI#&F/N+^5/I#TH`84CQG8OY4>6G]Q?RJGJ.K6NEPK)<R`
M;SM1!RSGT`IFCZQ'K5HUQ#%+$%D:-DE&&!7K235[%>SGR\UM"_Y:?W%_*CRT
M_N+^5.SQS3)94AB>5V"H@)8GH!3>A*5]A?+3^XOY4[RT_N+^58ND>)]-UNYE
M@M)"70;AN&-Z_P!X>U;8Z"A-/4J<)0?+-68GEI_<7\J/+3^XOY4ZB@D;Y:?W
M%_*CRT_N+^5.HH`;Y:?W%_*CRT_N+^5.HH`;Y:?W%_*L_6T0:1.0B_P]A_>%
M:59^N?\`('G_`.`_^A"@"Y'_`*M/]T5POCC49[W5],\,VTAC^V/NG=>NP=OQ
MKND/[I/H*\ZU\&Q^+&CW,O$,Z;%8]`143;L=V7Q3JN6[2;7JBQH\D3_%"YM8
M%5+>QL1'$@_AR1FN^^E>2V^I1>'_`(K:K+<[B'@`55&68GD`"KMCJVN>)?&5
MW8R3-91VT!DB@4X.XC`#>M90J)+SN=N+P,JC4T[14$[_`->9Z:<\8X%>+)<O
MJVN:ZO#W-W=I;)QD[4;)_05T&CZAXJTK5CHL\!N))8_,BDG?@$<$Y'.*Y_P?
M,EEJNN7LT:2:F9VBA53QO)[?YZ43G>QI@\+[%5'=2T5K>I[+"@@@2-<D*H`]
MZE#9KR[P/XCO8;C7GUJ\>5;=B2">`PXPM5],\1ZO#\09)-5N&CMG@:0P`_*B
M8R./6K]JK+S.265UN>:NGRJ_KZ'K6ZDW\=*\ITO7=9F^)UNEW<LEK<1.XMP?
ME5,?+GW[U+J?C>^LO&<5UY<K:-(#!&J_\MF'<>^>*/:JUQ?V56<^2.KM?_@'
MJ6[V-&X8)KRW7M5UN^\1Z3ILET;&.[(=H8CA@GNWJ:GNY_$WAW75PYN8KJ?R
M8FE;]V0>%]P11[7R)_LZ5H^\KM7^X]*WCG@\4;O8UY3%JNJZ+\1C!J>J--";
M=I)5Z(OT%)I^N:Q/\3+9;B=TMKF(NEMGA4/3(]:?M$7_`&54LY*2M:_J>K[A
MFDDD$<;.>B@DUG:EKVF:3-'%>72QRR?=0`EC^`K&A\4QZKJU]H\*`C[.9(IE
M;.X$<CV-4Y(XH8>I)<R6GZ',6>IOJJ^(/%=P=T=FK16*D_*@Z$X]:ZSP&,^#
M[&3.7D!=B>Y-<'H,3GX7>([`C;<1/)O3TR:L:'XQFT[P`L>G0-+=6T;&1R/D
MA`Z$UA&>JOV/;Q&%E5IN%-:J27RL>LCZ5R?Q'NWM?!-\(V*M(NP,.V37-6UO
MXFOO#5EJEO?3SSRL9IT1L'_9P.F!Z51\2ZQK>M>`FFN;>"*%&\N5R?G=QP<#
MI53J7BSFPF`Y<3!N2=I:^6IT/@>`7&HQ742@16UA'`6'1F(R?RKOPW;&*\>U
MG4+G3_!%O;Z$_P!FBMK=);N53\Q=AD+GUKH]6UV_/A*RM;&0'49K,32R$_ZM
M`.6/OFG":2L&*P<ZM15$])-K7I;N=\6`ZTNX5Y+HGB74Y?`2V\%PTNI2"1O.
M<Y,:#)W'^57?"7B>ZA^'[W-Q*]S>ES%!N.6=STIJK%NQC/*ZL$W?9V_X/H>F
M%P.M+NKS#PCXLUB\L+C2##OU6!V,DLI^6-<\D_CP!570%UWQ'IVLWD>J3/=1
M7'DHN=HV@Y.`.A-"JIVLMPEE=2FY>TDERV_'8]9S1D"O+X=1\37>EZE8-.+0
MZ>A+S/S*1C('I^-5-"\3ZK/X':UCN&EU*1G"2N<E4`R6)H]JKI-#_LNHTVI+
M1I??U/6]PJAKG_('G_X#_P"A"N6^%^H7FH>&96O+A[AXKAD#L<G'UKJ=;_Y`
M\_\`P'_T(5<9*2NCAQ-!T*LJ4M;%R/\`U:?[HK"\7:+;ZOI#-+)Y,UL?.AF[
MHPYK=3_5)_NBN:\92F2/3M,5MHOKE8W_`-T<G^5$EIJ/#<WM8N+L<)HYOKGX
MC:9J&JQH)KN$%0H[`8!K=\1>'=>T_P`5?\)%X<19GE4)+`3C/_UJUFL4N_B/
M"Z`>78VF#M_A9N@_*NNVYQFLXTTU\STL1F$XU(SBE\-K=+=CE/#FE:Q+J<FM
MZZ8UNFC\J*!.D2YR>?7-8WA#P5=6'BC4M5U)``9F:V7.1R?O?7'%>C;0:-HJ
M^1:'%]>J+G4;+F5OD>9>'O!&H0^*[^YU+`T\SF6-,Y\TYR,^PJ?4O!=YJOQ&
M74I`%TU5#LP;DD?PXKT;:/2C:,YQ2]E$T_M*OSN:>MK?(\UU[PCJU]X^AO;7
M$5DT1CDE!^ZIX('OBF^)O!NH:AK-G;VD!-A`B+%*'P(<'YB1W)KTS:/2C`H]
MDAQS.M%Q:M[JL<'XT\)7]^+#4M'D']HV&`H;^,"C2M/\3:[J-I=>(8XK2WLV
MWI"ARSOV)KO,"C:,YH]FKW,UCJGLU3:6E[/JKGG.M>#+W6/B'#?2+C35C'F/
MG[Q!^[]*C\3^%]=F\;VNI:,B+$8%A\TXQ#CN17I6T9S1M%#IQ*AF-:+B]'96
M^1RM_P""K:]6RG^U31ZA:)M2Z!W,?J#UK*LO`4L'B9KR:\FECDB(DE4",EO3
M"UW^T48INFF9PQU>,7%/38\QU[P])H.H/%H,@)U6-EG@F8MTZOFG?#[2X]3^
M'MWITH"^=+(C'')Y[UM6,ZWFNZ_J$Q^6S0V\6?X<`[OSXJQX`L6LO"T3,"#<
M.T_(_O&H45S7Z'?5Q52-#DE\2<7?K?\`X"L<II6E^.]%MY="MHX7M"2([ISP
M@/IWK<U[PG<GP&-&T\>=<C!8D_>;/)YKN0`:-HS5*FDCDEF-1U%422:=]%N_
M,\_U+P;<P_#AM'LE$UZ0&?)^^W<9J[HOAFYL/"5Q%<_O=3N+?8Q/8!<*E=GM
M%&T4>S5[DRS"M*')+OS?,\Z\'>"[O2?"]]'>*!J%S$R*I.=@(^[^=5O!W@O5
M]-TV5[\JMQ"CBSBZA'(^\?>O3MHHP*/9Q314LRKRY[_:W^1Y[X(\*W^G:Q?:
MG?Q&'SD$?ELVXNW4MGT)K/BT'Q9X2UJ[.AP1WEC=N7VLV-I)ZFO4MHQC%&!0
MJ45L/^T:KG*4DFI6NGMIL<CIGAV]MM!U,7LJ3:IJ`9I'7H"1@*/:LGP5X)NM
M*T.^-\%6]N59%4G(1:]$P/2C`]*/9K3R(6/K*,HK[33?R/./`?AC7M+F>+46
M,%C%,TJ1*W,K'H3CM[5W&M_\@>?_`(#_`.A"KX4"J&N?\@>?_@/_`*$*J,%%
M61EB<1+$5'4E:_D78_\`5I_NBN>\6^'KS7(+233KM+6]M9A)'*ZY`JRGB2R$
M:CR[CH/X1_C3AXDLC_RRG_[Y'^--HSI5)4IJ<=T+H&BMI5L[7,YN;Z8[IYR,
M;SV_`5KXK''B2SS_`*N?_OD?XTO_``DEG_SRG_[Y'^--*Q,YN<N9FQ16/_PD
MEG_SRG_[Y'^-'_"26?\`SRG_`.^1_C02;%%8_P#PDEG_`,\I_P#OD?XT?\))
M9_\`/*?_`+Y'^-`&Q16/_P`))9_\\I_^^1_C1_PDEG_SRG_[Y'^-`&Q16/\`
M\))9_P#/*?\`[Y'^-'_"26?_`#RG_P"^1_C0!L45C_\`"26?_/*?_OD?XT?\
M))9_\\I_^^1_C0!L4&L?_A)+/_GE/_WR/\:0^)+/_GG/_P!\C_&@#GY?!.H/
MKM[(FJB+2;V023VRK\[GTSV%=K'&L,:QH`$48`'85D_\))9YSY<__?(_QI?^
M$DL_^><__?(_QJ5%)FU;$3JVYWL;`I:QAXDL_P#GG/\`]\C_`!I?^$DL_P#G
ME/\`]\C_`!JC$V**Q_\`A)+/_GE/_P!\C_&C_A)+/_GE/_WR/\:`-BBL?_A)
M+/\`YY3_`/?(_P`:/^$DL_\`GE/_`-\C_&@#8HK'_P"$DL_^>4__`'R/\:/^
M$DL_^>4__?(_QH`V**Q_^$DL_P#GE/\`]\C_`!H_X22S_P">4_\`WR/\:`-B
ML_7/^0//_P`!_P#0A5?_`(22S_YY3_\`?(_QJAK'B*S?2IE\N<9V_P`(_O#W
$H`__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
